[177Lu]Lu-DOTA-MGS5的放射性药物制剂与初步临床剂量学:用于肽受体放射性核素治疗
本研究用自动化合成模块制备[177Lu]Lu-DOTA-MGS5,5批产品放射化学纯度均>98%且稳定性高;在A431-CCK2R荷瘤小鼠中显示有利的生物分布,小鼠药代动力学与剂量学外推证明PRRT可行;小细胞肺癌患者初步剂量学显示毒性风险低,可勾画肿瘤病灶平均吸收剂量为12.5 ± 10.2(1.2-28)Gy/GBq;结果支持启动首次临床试验评估其治疗潜力。
要点
- 自动化盒式生产5批[177Lu]Lu-DOTA-MGS5,放射化学纯度>98%且稳定性高。
- A431-CCK2R荷瘤BALB/c裸鼠生物分布有利,小鼠药代与剂量学外推证明PRRT可行。
- 小细胞肺癌患者初步剂量学显示毒性风险低,可勾画肿瘤病灶平均吸收剂量12.5 ± 10.2(1.2-28)Gy/GBq。
核心结论
- 放射性药物开发及临床前/临床结果支持启动首次临床试验,以评估[177Lu]Lu-DOTA-MGS5在PRRT中的治疗潜力。
研究设计与样本
- 研究合成5批[177Lu]Lu-DOTA-MGS5并按预设质量控制标准分析,开展细胞实验与荷瘤小鼠生物分布研究。
- 在A431-CCK2R异种移植BALB/c裸鼠中完成临床前剂量学,并在1例小细胞肺癌患者中完成首次剂量学研究。
主要发现
- 自动化盒式生产所得[177Lu]Lu-DOTA-MGS5放射化学纯度>98%且稳定性高。
- 新放射性药物在A431-CCK2R异种移植BALB/c裸鼠中显示有利的生物分布特征。
- 小鼠药代动力学数据与剂量学外推证明PRRT可行。
- 患者初步个体化剂量学显示毒性风险低,可勾画肿瘤病灶平均吸收剂量为12.5 ± 10.2(1.2-28)Gy/GBq。
关键数值与推荐
- 5批[177Lu]Lu-DOTA-MGS5均按预设质量控制规范分析,放射化学纯度>98%且稳定性高。
- 可勾画肿瘤病灶平均吸收剂量为12.5 ± 10.2(1.2-28)Gy/GBq。
临床怎么用
- 原文结论为放射性药物开发及临床前/临床结果支持启动首次临床试验,以评估[177Lu]Lu-DOTA-MGS5在PRRT中的治疗潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiolabelled minigastrin (MG) analogues targeting the cholecystokinin-2 receptor (CCK2R) have proven to be a promising approach for peptide receptor radionuclide therapy (PRRT). In this study, we report on the radiopharmaceutical development and standardization of the preparation of [177Lu]Lu-DOTA-MGS5 using an automated synthesis module. Furthermore, we present the preclinical tests required to move forward towards a first therapeutic clinical trial as well as preliminary clinical dosimetry data. METHODS: Five individual batches of [177Lu]Lu-DOTA-MGS5 were synthesized and analysed according to predefined quality control specifications. Cell-based experiments and biodistribution studies were performed to evaluate the specific receptor binding and tumour uptake of the radiopharmaceutical formulation. A preclinical dosimetry study was carried out in tumour xenografted mice and a first dosimetry study was performed in a patient with small cell lung cancer. RESULTS: The automated cassette-based production of [177Lu]Lu-DOTA-MGS5 resulted in a product with high radiochemical purity of > 98% and high stability. The new radiopharmaceutical showed a favourable biodistribution profile in A431-CCK2R xenografted BALB/c nude mice. Pharmacokinetic data obtained in mice and dosimetry extrapolation demonstrated the feasibility of PRRT. In the preliminary patient-specific dosimetry study, a low risk of toxicity was shown and a mean absorbed dose of 12.5 ± 10.2 (1.2-28) Gy/GBq was calculated for delineable tumour lesions. CONCLUSION: The radiopharmaceutical development and the preclinical/clinical results support the initiation of a first clinical trial to evaluate the therapeutic potential of [177Lu]Lu-DOTA-MGS5 in PRRT.
引用
- Zavvar TS, Hörmann AA, Konijnenberg M, et al. Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2024. PMID: 39643727. doi:10.1007/s00259-024-06979-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。